BCI-121 NEW
| Price | $60 | $98 | $197 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-19 |
Product Details
| Product Name: BCI-121 | CAS No.: 432529-82-3 |
| Purity: 99.67% | Supply Ability: 10g |
| Release date: 2025/05/19 |
Product Introduction
Bioactivity
| Name | BCI-121 |
| Description | BCI-121 is a substrate-competitive SMYD3 inhibitor that inhibits the proliferation of the cancer cell. |
| Cell Research | Cell proliferation is determined using the cell proliferation reagent WST-1. Cells are seeded into 96-well plates one day before treatment. After 48 h, 72 h, or 96 h of BCI-121 or DMSO exposure, 10 μL of the Cell Proliferation Reagent WST-1 are added to each well and incubated at 37 °C in a humidified incubator for up to 1 h. Absorbance is measured on a microplate reader at 450/655 nm. The proliferation index is calculated as the ratio of WST-1 absorbance of treated cells to WST-1 absorbance of control cells. |
| In vitro | BCI-121 significantly reduced the proliferation of HT29 (by 46%) and HCT116 (by 54%) cells at 72 h and decreased the expression levels of SMYD3 target genes. BCI-121 treatment only affected proliferation of cancer cell lines expressing high levels of SMYD3. The high levels of SMYD3 expression detected in OVCAR-3 cells, along with the strong reduction in proliferation rate observed upon BCI-121 treatment. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 100 mg/mL (293.93 mM), Sonication is recommended. |
| Keywords | SMYD3 | Inhibitor | inhibit | HistoneMethyltransferase | Histone Methyltransferase | BCI-121 | BCI121 | BCI 121 |
| Inhibitors Related | MAK-683 hydrochloride | BIX-01294 trihydrochloride | ORIC-944 | Tazemetostat | Piribedil | XY1 | MAK683 | EPZ015666 | iso-Azalansta | AMI-1 free acid | MS37452 | MRTX-1719 |
| Related Compound Libraries | Histone Modification Compound Library | Reprogramming Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Epigenetics Compound Library | Chromatin Modification Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1bag |
VIP1Y
|
Xi an Biohorlden Industry Trade Co Ltd
|
2025-04-14 | |
| $52.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-06-12 | |
| $0.00/10mg |
VIP2Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2024-07-11 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY